Frances K. Heller Rejoins Zafgen Board of Directors Read more about Frances K. Heller Rejoins Zafgen Board of Directors Zafgen Reports Second Quarter 2014 Financial Results Read more about Zafgen Reports Second Quarter 2014 Financial Results Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference Read more about Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference Zafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome Read more about Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome Zafgen Appoints Patrick Loustau as President Read more about Zafgen Appoints Patrick Loustau as President Zafgen Appoints New Member of Board of Directors Read more about Zafgen Appoints New Member of Board of Directors Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Read more about Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Zafgen, Inc. Announces Pricing of Initial Public Offering Read more about Zafgen, Inc. Announces Pricing of Initial Public Offering Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013 Read more about Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013 Pagination First page « First Previous page ‹ Previous … Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Page 24 Page 25 Next page Next › Last page Last » Subscribe to
Frances K. Heller Rejoins Zafgen Board of Directors Read more about Frances K. Heller Rejoins Zafgen Board of Directors
Zafgen Reports Second Quarter 2014 Financial Results Read more about Zafgen Reports Second Quarter 2014 Financial Results
Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference Read more about Zafgen to Present at 34th Annual Canaccord Genuity Growth Conference
Zafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results Read more about Zafgen to Host Conference Call to Discuss Second Quarter 2014 Financial Results
Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome Read more about Zafgen Granted Orphan Drug Designation in the European Union for Beloranib, a First-in-Class MetAP2 Inhibitor for the Treatment of Prader-Willi Syndrome
Zafgen Appoints Patrick Loustau as President Read more about Zafgen Appoints Patrick Loustau as President
Zafgen Appoints New Member of Board of Directors Read more about Zafgen Appoints New Member of Board of Directors
Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option Read more about Zafgen, Inc. Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option
Zafgen, Inc. Announces Pricing of Initial Public Offering Read more about Zafgen, Inc. Announces Pricing of Initial Public Offering
Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013 Read more about Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013